Most cited papers in Histone Deacetylase Inhibitors Research
What are the most cited papers in Histone Deacetylase Inhibitors Research?
The most cited paper in Histone Deacetylase Inhibitors Research is "Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel" (Hartmut Döhner et al., 2016), with 5,972 citations. Next come "A simple method for clinical assay of superoxide dismutase." (4,529) and "The Epigenomics of Cancer" (4,489).
Showing 50 of 100 papers. Every paper with more than 1,231 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Hartmut Döhner et al. · Blood | 28 Nov 2016 | 5,972 |
| 2 | A simple method for clinical assay of superoxide dismutase. Yi Sun, Larry W. Oberley, Yi Li · Clinical Chemistry | Mar 1988 | 4,529 |
| 3 | The Epigenomics of Cancer Peter Anthony Jones, Stephen B. Baylin · Cell | Feb 2007 | 4,489 |
| 4 | Selective inhibition of BET bromodomains P. Filippakopoulos et al. · Nature | 24 Sep 2010 | 4,363 |
| 5 | Cancer Metastasis: Building a Framework Gaorav P. Gupta, Joan Massagué · Cell | Nov 2006 | 4,346 |
| 6 | Malignant Gliomas in Adults Patrick Yung Wen, Santosh Kesari · New England Journal of Medicine | 30 Jul 2008 | 4,283 |
| 7 | Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions Chunaram Choudhary, Chanchal Kumar, Florian Gnad et al. · Science | 16 Jul 2009 | 4,088 |
| 8 | Epigenetics in Cancer Manel Esteller · New England Journal of Medicine | 12 Mar 2008 | 3,708 |
| 9 | MYC on the Path to Cancer Chi V. Dang · Cell | Mar 2012 | 3,481 |
| 10 | Cancer Epigenetics: From Mechanism to Therapy Mark A. Dawson, Tony Kouzarides · Cell | Jul 2012 | 3,269 |
| 11 | Histone deacetylases (HDACs): characterization of the classical HDAC family Annemieke J.M. de Ruijter, Albert H. Gennip, Huib N. Caron et al. · Biochemical Journal | 12 Mar 2003 | 3,118 |
| 12 | Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor Peter E. Angel, Masayoshi Imagawa, Robert Chiu et al. · Cell | Jun 1987 | 3,027 |
| 13 | Modes of resistance to anti-angiogenic therapy Gabriele Bergers, Douglas Hanahan · Nature reviews. Cancer | 24 Jul 2008 | 2,965 |
| 14 | Anticancer activities of histone deacetylase inhibitors Jessica E. Bolden, Melissa J. Peart, Ricky W. Johnstone · Nature Reviews Drug Discovery | Sep 2006 | 2,936 |
| 15 | A decade of exploring the cancer epigenome — biological and translational implications Stephen B. Baylin, Peter Anthony Jones · Nature reviews. Cancer | 23 Sep 2011 | 2,921 |
| 16 | Histone acetylation in chromatin structure and transcription Michael Grunstein · Nature | Sep 1997 | 2,921 |
| 17 | Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases Wei Xu et al. · Cancer Cell | 2011 | 2,920 |
| 18 | Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia Courtney Denton Dinardo et al. · New England Journal of Medicine | 12 Aug 2020 | 2,918 |
| 19 | The molecular hallmarks of epigenetic control C. David Allis, Thomas Jenuwein · Nature Reviews Genetics | 27 Jun 2016 | 2,917 |
| 20 | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Jake E. Delmore et al. · Cell | Sep 2011 | 2,889 |
| 21 | A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations Sreenath V. Sharma, Diana Wing Lee, Bihua Li et al. · Cell | Apr 2010 | 2,858 |
| 22 | Angiogenesis as a therapeutic target Napoleone Ferrara, Robert S. Kerbel · Nature | Dec 2005 | 2,666 |
| 23 | Epigenetics in cancer Shilpa Sharma, T. K. Kelly, Peter A. Jones · Carcinogenesis | 13 Sep 2009 | 2,613 |
| 24 | Targeting cancer with small molecule kinase inhibitors Jianming Zhang, Priscilla Li-ning Yang, Nathanael S. Gray · Nature reviews. Cancer | 19 Dec 2008 | 2,601 |
| 25 | Combination therapy in combating cancer Reza Bayat Mokhtari, Tina S. Homayouni, Narges Baluch et al. · Oncotarget | 30 Mar 2017 | 2,568 |
| 26 | The many roles of histone deacetylases in development and physiology: implications for disease and therapy Michael Haberland, Rusty L. Montgomery, Eric N. Olson · Nature Reviews Genetics | 9 Dec 2008 | 2,568 |
| 27 | Macrophage M1/M2 polarization Chen Yunna, Mengru Hu, Lei Wang et al. · European Journal of Pharmacology | 29 Mar 2020 | 2,512 |
| 28 | Drug Resistance in Cancer: An Overview Genevieve Housman, Shannon Byler, Sarah Heerboth et al. · Cancers | 5 Sep 2014 | 2,488 |
| 29 | HDAC6 is a microtubule-associated deacetylase Charlotte C. Hubbert, Amaris R. Guardiola, Rong Shao et al. · Nature | May 2002 | 2,409 |
| 30 | Multiple Myeloma Antonio Pierangelo Palumbo, Kenneth Carl Anderson · New England Journal of Medicine | 16 Mar 2011 | 2,360 |
| 31 | ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation Kathryn E. Wellen, Georgia Hatzivassiliou, Uma M. Sachdeva et al. · Science | 21 May 2009 | 2,327 |
| 32 | Distinct Role of Macrophages in Different Tumor Microenvironments Claire E. Lewis, Jeffrey W. Pollard · Cancer Research | 15 Jan 2006 | 2,240 |
| 33 | Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Saverio Minucci, Pier Giuseppe Pelicci · Nature reviews. Cancer | 2006 | 2,213 |
| 34 | A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors Yasutomi Kamei, Lan Xu, Thorsten Heinzel et al. · Cell | May 1996 | 2,186 |
| 35 | Tumor metastasis: mechanistic insights and clinical challenges Patricia Schriver Steeg · Nature Medicine | Aug 2006 | 2,152 |
| 36 | Erasers of Histone Acetylation: The Histone Deacetylase Enzymes Ed Seto, Minoru Yoshida · Cold Spring Harbor Perspectives in Biology | Apr 2014 | 2,048 |
| 37 | IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Şevin Turcan, Daniel Rohle, Anuj Goenka et al. · Nature | 14 Feb 2012 | 2,034 |
| 38 | IDH mutation impairs histone demethylation and results in a block to cell differentiation Chao Lü, Patrick S. Ward, Gurpreet Singh Kapoor et al. · Nature | 14 Feb 2012 | 2,012 |
| 39 | Regulation of Cellular Metabolism by Protein Lysine Acetylation Shimin Zhao et al. · Science | 18 Feb 2010 | 1,917 |
| 40 | Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions Michael A. Shogren‐Knaak, Haruhiko Ishii, Jian-Min Sun et al. · Science | 9 Feb 2006 | 1,915 |
| 41 | Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells Martin Göttlicher, Saverio Minucci, Ping Zhu et al. · The EMBO Journal | 17 Dec 2001 | 1,903 |
| 42 | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Johannes A. Zuber, Junwei Shi, Eric Wang et al. · Nature | Aug 2011 | 1,895 |
| 43 | Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Courtney Denton Dinardo, Keith William Pratz, Vinod A. Pullarkat et al. · Blood | 26 Oct 2018 | 1,886 |
| 44 | Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. Minoru Yoshida, Masako Kijima, Motomu Akita et al. · Journal of Biological Chemistry | Oct 1990 | 1,869 |
| 45 | Histone deacetylases and cancer: causes and therapies Paul A. Marks, Richard A. Rifkind, Victoria M. Richon et al. · Nature reviews. Cancer | Dec 2001 | 1,866 |
| 46 | Histone Acetyltransferases Sharon Y. Roth, John M. Denu, C. David Allis · Annual Review of Biochemistry | Jun 2001 | 1,856 |
| 47 | Histone acetylation and transcriptional regulatory mechanisms Kevin Struhl · Genes & Development | Mar 1998 | 1,828 |
| 48 | The CBP co-activator is a histone acetyltransferase Andrew J. Bannister, Tony Kouzarides · Nature | Dec 1996 | 1,826 |
| 49 | A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p JACK E. TAUNTON, Christian A. Hassig, Stuart L. Schreiber · Science | 19 Apr 1996 | 1,826 |
| 50 | Role of histone H2A ubiquitination in Polycomb silencing Hengbin Wang, Liangjun Wang, Hediye Erdjument‐Bromage et al. · Nature | 22 Sep 2004 | 1,806 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.